Business
Cencora Reports Fiscal 2025 Second Quarter Results
CONSHOHOCKEN, Pa., May 07, 2025--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, in
About this update from Cencora, Inc.
[{"type":"text","content":"Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-YearSecond Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025","length":241,"tagName":"p","attribs":{}},{"type":"text","content":"CONSHOHOCKEN, Pa., May 07, 2025--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 16.3 percent to $4.42 in the fiscal second quarter from $3.80 in the prior year second quarter.","length":620,"tagName":"p"},{"type":"text","content":"Cencora is updating its outlook for fiscal year 2025. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2025 Expectations. Adjusted diluted EPS guidance has been raised from the previous range of $15.30 to $15.60 to a range of $15.70 to $15.95.","length":298,"tagName":"p"},{"type":"text","content":""Cencora’s second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve."","length":501,"tagName":"p"},{"type":"text","content":""Cencora strives to enhance its leadership position in healthcare through our pharmaceutical centric strategy, best-in-class team members, and customer-focused approach." Mauch continued. "We believe this leadership, coupled with our operational excellence and emphasis on productivity, drives our resilient financial performance now and will continue to drive it in the future."","length":399,"tagName":"p"},{"type":"text","content":"Second Quarter Fisca...